Engerix-B Paediatric is a medicine containing the active ingredient(s) hepatitis b vaccine. On this page you will find out more about Engerix-B Paediatric, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: hepatitis b vaccine
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Engerix-B Paediatric 10 microgram/0.5 mL injection suspension, 0.5 mL vial
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
ENGERIX-B is indicated for active immunisation against hepatitis B virus infection. The NH&MRC* recommend all infants, young children and unvaccinated adolescents receive a primary course of immunisation against hepatitis B. The NH&MRC also recommends immunisation for persons who are at substantial risk and have been demonstrated or judged to be susceptible to the hepatitis B virus. Groups identified at increased risk of acquiring HBV infection include: Infants born to carrier (HBsAg-positive) mothers; Individuals for whom post-exposure prophylaxis for hepatitis B is indicated; Household contacts (other than sexual partners) of acute and chronic hepatitis B cases and carriers; susceptible sexual contacts. Risk occurs in susceptible (anti-HBs negative) partners of HBV carriers and patients with acute hepatitis B; Susceptible clients of STD (sexually transmitted disease) clinics, and sexually active men who have sex with men are also at increased risk of infection; Injecting drug users; Haemodialysis patients, HIV-positive individuals and other immunosuppressed adults; Patients receiving certain blood products especially patients with clotting disorders receiving blood product concentrates; Individuals with chronic liver disease and / or hepatitis C; Staff and residents of facilities for the intellectually disabled, including both residential and non-residential care of this group; Liver transplant recipients. Such individuals should be vaccinated prior to transplantation if seronegative for hepatitis B, as they may be at increased risk of infection from the transplanted organ; Staff and inmates of long term correctional facilities; Health care workers, dentists, embalmers, tattooists and body-piercers. All staff directly involved in patient care, embalming, or in the handling of human blood or tissue should be vaccinated; Individuals adopting children from overseas. These children should be tested for hepatitis B, and if HBsAg positive, members of the adoptive family should be vaccinated; Others in whom vaccination may be justified include police, members of the armed forces and emergency services staff, depending on the risks of exposure associated with assigned duties. Long term travellers to regions of high endemicity, and those residing for some time in such regions who may anticipate close personal contact with local residents, should be vaccinated. Short-term tourists or business travellers are at very little risk of hepatitis B, provided they avoid exposure through sexual contact, injecting drug use, tattooing or body piercing. Although the risk of hepatitis B infection in contact sports is low, immunisation of those involved should not be discouraged. As the risk in Australian schools is very low, vaccination of classroom contacts is seldom indicated. Nevertheless, vaccination of school children and adolescents should be encouraged; As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by vaccination with ENGERIX-B. The vaccine will not protect against infection caused by hepatitis A, hepatitis C and hepatitis E viruses, and other pathogens known to infect the liver.
Table of characteristics
|Visual appearance||Turbid liquid with a slow settling white deposit and a colourless supernatant. The precipitate is easily resuspended when shaken.|
|Dosage Form||Injection, suspension|
|Route of administration||Subcutaneous|
1 x 0.5mL: Prescription Only Medicine, or Prescription Animal Remedy
10 x 0.5mL: Prescription Only Medicine, or Prescription Animal Remedy
25 x 0.5mL: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Protect from Light,Do not Freeze|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.